During clinical trials, ClinicalTrialsUA and its partner sites utilize tools such as radiography, ultrasound, and magnetic resonance imaging to evaluate the extent of inflammation and changes in joints and tissues.
Functional tests are employed to measure patients’ physical capabilities, such as walking distance, hand grip strength, joint mobility, etc.
Electrocardiograms and cardiovascular monitoring are also utilized during clinical trials to study potential side effects on the cardiovascular system after administering specific medications.
Clinical trials in rheumatology conducted at ClinicalTrialsUA have led to the development and introduction of new medications into the pharmaceutical market. These medications have an evidence base and proven safety across all stages of treatment.
All medications have proven effective in combating the progression of symptoms associated with the disease.
ClinicalTrialsUA is continually advancing in clinical trials to enhance the quality of life for patients worldwide.
We’ve been part of the clinical research market for over 24 years, gaining extensive experience conducting high-quality and effective medication trials across 18 different therapeutic areas.
We exclusively partner with established companies and laboratories that share our core values: unwavering commitment to the highest quality, responsibility in facing challenges, adherence to deadlines and budgets, and a commitment to implementing innovations.
With ClinicalTrialsUA, you can always be confident in obtaining precise and reliable results.
Complex connective tissue diseases, also known as collagenoses or rheumatic diseases, are chronic conditions that affect the body’s connective tissue.
These diseases encompass a range of conditions, including systemic lupus erythematosus, rheumatoid arthritis, scleroderma, dermatomyositis, nodular periarteritis, ankylosing spondylitis, and others.
The relevance of these diseases is increasing in the modern world, emphasizing the need for clinical trials to explore new and effective ways to address rheumatic conditions.
The current challenge posed by systemic connective tissue diseases worldwide encompasses the following aspects:
- the rising occurrence of this type of disease
- the challenge of diagnosing these conditions
- a notable impact on the patient’s quality of life
- the necessity for genuinely effective treatment
- the demand for further research
Rheumatoid arthritis stands as one of the most prevalent conditions in the sphere of Rheumatology.
Rheumatoid arthritis is a persistent and progressive inflammatory disease that affects the entire body, leading to severe and irreversible joint damage, accompanied by pain and functional limitations.
In Europe, approximately 3 million patients dealing with rheumatoid arthritis cannot achieve sustained symptom control, resulting in disease progression and a decline in their quality of life.
While available treatments exist, there is still an urgent need for the creation and research of new medications to improve the daily lives of patients.
